PharmAbcine Obtains Patent Rights for Pharmaceutical Composition for Cancer Treatment

[Asia Economy Reporter Eunmo Koo] PharmAbcine announced on the 21st that it had obtained a patent from the Canadian Intellectual Property Office on the 9th for PMC-005BL, a novel drug candidate targeting the epidermal growth factor receptor variant III (hereinafter EGFRvIII).

The patent is titled "Novel EGFRvIII antibody and composition comprising same," which includes an antibody that specifically binds to EGFRvIII, a manufacturing method for the antibody, and a pharmaceutical composition for cancer or tumor treatment containing the antibody as an active ingredient.

EGFRvIII is a mutant protein that is not expressed in normal cells but is expressed only in cancer cells and cancer stem cells, promoting cancer cell growth. It is mainly found in patients with glioblastoma multiforme (GBM) and also appears in prostate cancer, ovarian cancer, breast cancer, and colorectal cancer. Since most EGFRvIII-positive patients have poor prognosis, it is considered an important therapeutic target in the field of oncology.

Utilizing technologies and materials related to EGFRvIII can enable the development of next-generation personalized cell therapies in formats such as antibody-drug conjugates (ADC), antibody-toxin conjugates (ATC), antibody-cytokine conjugates (ACC), antibody-radioisotope conjugates (ARC), CAR-T, CAR-NK, and CAR-Macrophage.

PMC-005BL, which received the patent in Canada, is planned to be developed as an anticancer agent using the dual-target CAR-T platform of the bio-venture company Qurocell, with which PharmAbcine signed a joint research agreement in March last year. PMC-005BL is also expected to be used not only as a cancer therapeutic but also as an imaging companion diagnostic method to accurately locate EGFRvIII-positive cancers.

Yujin San, CEO of PharmAbcine, stated, "The PMC-005BL patent has already been registered not only in Canada but also in Korea, Japan, Australia, and the United States. Additionally, patent examinations are underway in other countries such as Europe and China, and we plan to complete the final patent acquisition within a short period."

This content was produced with the assistance of AI translation services.